Physician profile
Robert L Chappell, JR.
NPI 1336116938
$11,812.13
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,740 · 2020: $2,008 · 2021: $2,395 · 2022: $3,362 · 2023: $1,230 · 2024: $76.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,824.04 | 2019-2023 | Rinvoq, Skyrizi |
| Amgen INC. | $1,065.96 | 2019-2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $1,060.96 | 2019-2023 | Ilumya |
| Novartis Pharmaceuticals Corporation | $889.30 | 2019-2023 | |
| Ucb, INC. | $740.62 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $665.34 | 2019-2023 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $664.97 | 2019-2023 | Dupixent |
| Genzyme Corporation | $613.21 | 2019-2023 | |
| Galderma Laboratories, L.P. | $547.81 | 2019-2023 | Epsolay, Oracea, Aklief |
| Leo Pharma INC. | $528.52 | 2022-2024 | Adbry |
| Janssen Biotech, INC. | $465.72 | 2019-2023 | Tremfya |
| Mayne Pharma Commercial LLC | $438.51 | 2019-2023 | |
| Celgene Corporation | $190.03 | 2019 | |
| Vyne Pharmaceuticals INC. | $183.81 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $152.60 | 2022-2023 | Sotyktu |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $145.25 | 2019-2021 | |
| Incyte Corporation | $121.63 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $108.67 | 2023 | |
| Dermira, INC. | $67.99 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $63.13 | 2019 | |
| Genentech USA, INC. | $56.82 | 2019-2022 | |
| Allergan, INC. | $53.06 | 2021 | |
| Almirall LLC | $38.99 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.50 | 2020 | |
| Journey Medical Corporation | $26.04 | 2022 | |
| Biofrontera INC. | $18.00 | 2020 | |
| Organogenesis INC. | $16.40 | 2020 | |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Prugen, INC. Pharmaceuticals | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.